[{"NetIncomeLossConverted_1_Q1_USD":653138000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q1_shares":259369000.0,"NetCashProvidedByUsedInOperatingActivitiesConverted_1_Q1_USD":921055000.0,"EarningsPerShareDiluted_1_Q1_USD":2.49,"CommonStockSharesOutstanding_0_Q1_shares":258829000.0,"StockholdersEquity_0_Q1_USD":8980254000.0,"RevenuesConverted_1_Q1_USD":1724305000.0,"Assets_0_Q1_USD":12115059000.0,"CommonStockSharesConverted_0_Q1_shares":258829000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q1_shares":261916000.0,"EarningsPerShareBasic_1_Q1_USD":2.52,"Ticker":"VRTX","CIK":"875320","name":"VERTEX PHARMACEUTICALS INC \/ MA","OfficialName":"Vertex Pharmaceuticals Incorporated Common Stock","form":"10-Q","period":"20210331","fy":"2021.0","fp":"Q1","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"72193451271.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"SP500","filed":"20210430"}]